8-K: Lifecore Biomedical Q2 2026: Revenue Declines, Guidance Reaffirmed

Lifecore Biomedical reported a decrease in revenue and gross profit for Q2 2026 compared to the prior year, while reaffirming its full-year financial guidance and highlighting new business wins.

Summary

• Lifecore Biomedical announced its financial results for the second quarter and six months ended June 30, 2026.
• Revenues for Q2 2026 were $34.2 million, a 6.2% decrease from $36.4 million in the prior year quarter.
• For the six months ended June 30, 2026, revenues were $57.4 million, a 19.9% decrease from $71.6 million in the prior year period.
• Gross profit for Q2 2026 was $12.1 million, down from $14.0 million in the prior year quarter.
• Net loss for Q2 2026 was $6.2 million ($0.19 loss per diluted share), compared to a net loss of $1.1 million ($0.06 loss per diluted share) in the prior year quarter.
• Adjusted EBITDA for Q2 2026 was $8.6 million, a decrease from $9.1 million in the prior year quarter.
• The company reaffirmed its 2026 financial guidance, expecting revenues between $120 million and $125 million and Adjusted EBITDA between $20.5 million and $25 million.
• Lifecore signed six new programs in Q2 2026, including two commercial-stage programs, and a total of 13 programs in the last 12 months, with eight being late-stage.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a mixed to slightly negative report due to declining revenues and profits, despite reaffirming guidance and highlighting pipeline growth.

Positives

• Reaffirmed 2026 revenue guidance of $120-$125 million and Adjusted EBITDA guidance of $20.5-$25 million.
• Secured six new business wins in Q2 2026, including two commercial-stage programs.
• Added eight late-stage programs to the pipeline over the last 12 months, contributing to long-term growth objectives.
• Progressed over 40 projects aimed at cost reduction and productivity improvements, expected to enhance margins.
• Successfully completed seven audits (five customer, two regulatory) in Q2 2026, reinforcing its reputation for quality and compliance.
• Ended Q2 2026 with $38.8 million in liquidity, including $17.2 million in cash and $21.6 million in revolving credit availability.
• Cash from operations was $2.5 million and free cash flow was $0.9 million for the six months ended June 30, 2026.

Negatives

• Revenues decreased by 6.2% to $34.2 million in Q2 2026 compared to the prior year quarter.
• Six-month revenues decreased by 19.9% to $57.4 million compared to the prior year period.
• Gross profit decreased by 14% to $12.1 million in Q2 2026 compared to the prior year quarter.
• Net loss widened to $6.2 million in Q2 2026 from $1.1 million in the prior year quarter.
• Adjusted EBITDA decreased by $0.5 million to $8.6 million in Q2 2026 compared to the prior year quarter.
• Operating expenses increased by 9.9% to $9.5 million in Q2 2026 compared to the prior year quarter.

Risks

• The company is unable to predict with reasonable certainty the ultimate outcome of certain significant items (restructuring expenses, reorganization expenses, asset impairments, litigation settlements, changes to debt derivative liability fair value, etc.) which could materially impact reported results.
• Potential loss of development customers if they do not receive required funding or regulatory approvals.
• Ability to comply with covenants under credit agreements and make timely interest and principal payments.
• Ability to fund or pay redemptions of Series A Convertible Preferred Stock.
• Ability to raise additional capital through equity, debt, collaborations, or licensing.
• Impact of macroeconomic events (inflation, tariffs, interest rates, social unrest, global instability) on operations and financial performance.
• Performance of third-party suppliers.
• Pharmaceutical industry market forces impacting customer success and demand for Lifecore's products.

Future Outlook

The company reaffirms its 2026 guidance, expecting revenues between $120 million and $125 million and Adjusted EBITDA between $20.5 million and $25 million. Long-term objectives include achieving a 12% revenue CAGR and Adjusted EBITDA margins exceeding 25% by the end of 2029. The company anticipates a significant inflection point in demand starting in 2027, with projected growth in fill-finish contractual demand.

Management Comments

• "The second quarter was highly productive. The effectiveness of our new business development strategy has helped us grow the value of our pipeline with consistent wins that point to our manufacturing expertise as well as our exceptional track record in quality and compliance."
• "In addition, Lifecore continues to transition our development pipeline toward commercialization and invest in the talent, processes, and improvements that we believe will support our growing pipeline in the mid-term and allow us to achieve sustainable, long-term profitability in the future."
• "In the past 12 months, we have added 13 new programs to our pipeline, eight of which are late stage. We expect these programs and their financial contributions to play a significant role in Lifecores success in achieving our long-term growth objectives of a 12% revenue CAGR and Adjusted EBITDA margin targets exceeding 25% by the end of 2029."

Industry Context

StockSavvy.ai notes that Lifecore operates in the growing global injectable CDMO market, which is experiencing an accelerated demand for US-based manufacturing. The company's focus on sterile injectables and hyaluronic acid positions it within a segment that benefits from strong tailwinds, including the increasing prevalence of injectable drugs and the significant growth projected for markets like GLP-1.

Comparison to Industry Standards

• The company aims for long-term growth objectives of a 12% revenue CAGR and Adjusted EBITDA margin targets exceeding 25% by the end of 2029, which are ambitious targets within the CDMO sector.
• Lifecore's reported Q2 2026 Adjusted EBITDA margin was approximately 25.1% ($8.6M / $34.2M), aligning with its target range for the year (17%-20%) but below its long-term goal.
• The company's stated annual production capacity of $300M is a significant asset, aiming for higher utilization rates to drive efficiency, a common industry goal for CDMOs.
• The successful completion of multiple customer and regulatory audits in a single quarter is a positive indicator of quality and compliance, a critical benchmark for CDMOs in the pharmaceutical industry.

Related Party Transactions

• Accounts receivable, related party: $16.7 million as of June 30, 2026.
• Interest expense, related party: $7.3 million for Q2 2026, $14.2 million for the six months ended June 30, 2026.
• Debt, net of current portion, related party: $148.5 million as of June 30, 2026.
• Debt derivative liability, related party: $30.9 million as of June 30, 2026.

Stakeholder Impact

• Shareholders: Negative impact due to declining revenues, widening net loss, and reduced Adjusted EBITDA in Q2 2026, despite reaffirmed guidance.
• Creditors: Potential concern due to increased debt levels and the need to comply with credit agreement covenants.
• Employees: Potential positive impact from investments in talent and processes aimed at long-term growth and profitability.
• Customers: Continued validation of quality and compliance through successful audits may strengthen relationships.

Next Steps

• Continue to transition development pipeline toward commercialization.
• Invest in talent, processes, and improvements to support growing pipeline and achieve long-term profitability.
• Continue to progress cost reduction and productivity enhancement projects.
• Focus on achieving 2026 revenue guidance of $120-$125 million and Adjusted EBITDA guidance of $20.5-$25 million.
• Work towards long-term objectives of 12% revenue CAGR and Adjusted EBITDA margins exceeding 25% by end of 2029.
• Anticipate an inflection point in demand beginning in 2027.

Key Dates

Recommendation

The company is facing declining revenues and profitability, which is a significant concern. However, it is reaffirming its full-year guidance and has a strong pipeline of new business and late-stage programs. The successful completion of audits and strong liquidity provide some stability. The recommendation is 'hold' due to the mixed signals: negative short-term financial performance offset by positive long-term strategic initiatives and pipeline development.

Keywords

CDMO, Injectable Pharmaceuticals, Contract Development, Manufacturing, Hyaluronic Acid, Sterile Injectables, Biopharmaceutical, Biotechnology